Glaukos (GKOS)
(Delayed Data from NYSE)
$122.77 USD
+2.04 (1.69%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $122.76 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GKOS 122.77 +2.04(1.69%)
Will GKOS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GKOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GKOS
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
GKOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
Strength Seen in CVRx (CVRX): Can Its 19.0% Jump Turn into More Strength?
Baxter (BAX) Shares Rise 2.4% in July: Will It Go Higher?
Other News for GKOS
Healthcare 2024 Second Half Outlook
Glaukos price target raised by $16 at Truist, here's why
Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
4 constructive medical devices stocks - BTIG